This page contains the list of companies in Drug Manufacturers - Other category. Click on the company name to get further details of the company.
ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California. ISTA Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company with products and product candidates for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The Company has three products available for sale in the United States: Xibrom, (bromfenac ophthalmic solution) for the treatment of inflammation and pain following cataract surgery, Istalol, (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase (hyaluronidase for injection) for use as a spreading agent. The Company also has several product candidates in various stages of development. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma.
Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.
King Pharmaceuticals was founded in 1993 and is headquartered in Bristol, Tennessee. King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. The companys branded prescription pharmaceuticals include neuroscience products, such as Skelaxin, Avinza, and Sonata; hospital products, including Thrombin-JMI and Synercid; acute care products that comprise Bicillin and Intal; and legacy products consisting of Altace, Levoxyl, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. Its animal health business focuses on medicated feed additives (MFAs) and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets.King Pharmaceuticals Inc. also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. King Pharmaceuticals also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan and Adenocard. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. Adenocard is a sterile solution of adenosine administered intravenously in emergency situations to convert certain irregular heart rhythms to normal sinus rhythms. It distributes its branded pharmaceutical products through wholesale pharmaceutical distributors and a sales force.
Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania. Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. Lannett company's products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules. In addition, its products consist of pilocarpine HCl, primidone, probenecid, terbutaline sulfate, and unithroid tablets; oxycodone HCl oral solution; rifampin and ursodiol capsules; and phentermine HCl tablets and capsules. Lannett Company markets its products under the brand names of Diamox, Symmetrel, Lioresal, Urecholine, Fiorinal, Cleocin, Danocrine, Bentyl, Lanoxin, Persantine, Adoxa, Periostat, Estratest, Hydrodiuril, Dilaudid, Levoxyl/ Synthroid, Roxanol, PrimaCare ONE, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Actigall, and Fiorinal w/ Codeine #3. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.
Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.
MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.
Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.
MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.
NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).
NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.